A Bayesian adaptive design for dual-agent phase I-II cancer clinical trials combining efficacy data across stages
share
Integrated phase I-II clinical trial designs are efficient approaches to accelerate drug development. In cases where efficacy cannot be ascertained in a short period of time, two-stage approaches are usually employed. When different patient populations are involved across stages, it is worth of discussion about the use of efficacy data collected from both stages. In this paper, we focus on a two-stage design that aims to estimate safe dose combinations with a certain level of efficacy. In stage I, conditional escalation with overdose control (EWOC) is used to allocate successive cohorts of patients. The maximum tolerated dose (MTD) curve is estimated based on a Bayesian dose-toxicity model. In stage II, we consider an adaptive allocation of patients to drug combinations that have a high probability of being efficacious along the obtained MTD curve. A robust Bayesian hierarchical model is proposed to allow sharing of information on the efficacy parameters across stages assuming the related parameters are either exchangeable or nonexchangeable. Under the assumption of exchangeability, a random-effects distribution is specified for the main effects parameters to capture uncertainty about the between-stage differences. The proposed methodology is assessed with extensive simulations motivated by a real phase I-II drug combination trial using continuous doses.
READ FULL TEXT